Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Boston's Rgenta Raises $20 Million for RNA Therapies from China-Heavy Syndicate

publication date: Apr 2, 2020

Rgenta Therapeutics, a Cambridge, Mass. biotech startup, raised $20 million in seed funding from a syndicate that includes China investors. The company is developing small molecule candidates that target RNA regulation and splicing of disease-causing genes in oncology and neurological disorders. The targets are undruggable by traditional approaches, Rgenta says. The funding was co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China, and it also included Hangzhou Kaitai Capital and Legend Star Fund, an offshoot of China's Lenovo Group. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here